Molnupiravir wallpaper Molnupiravir, Merck And Ridgeback S Investigational Oral Antiviral Molnupiravir Reduced The Risk Of Hospitalization Or Death By Approximately 50 Percent Compared To Placebo For Patients With Mild Or Moderate Covid 19 In Positive Interim Analysis Russell Wade Oktober 05, 2021 Ruchika 7 Dec 2020 1100 AM GMT. Molnupiravir is currently also being assessed in newly hospitalised patients with COVID with this study aimi...